{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:57:56Z","timestamp":1785481076341,"version":"3.56.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40123-026-01397-y","type":"journal-article","created":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T10:15:05Z","timestamp":1782728105000},"page":"2681-2694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological Characterization of a Novel Complement C3 Inhibitor Antibody Fragment"],"prefix":"10.1007","volume":"15","author":[{"given":"Stephanie","family":"Jungmichel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kreidewei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Scheifele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sobieraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Richle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lenherr-Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1449-2862","authenticated-orcid":false,"given":"Remko A.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Borras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"1397_CR1","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.molimm.2015.02.032","volume":"67","author":"S McHarg","year":"2015","unstructured":"McHarg S, Clark SJ, Day AJ, Bishop PN. Age-related macular degeneration and the role of the complement system. Mol Immunol. 2015;67:43\u201350.","journal-title":"Mol Immunol"},{"key":"1397_CR2","first-page":"S2","volume":"29","author":"SJ Bakri","year":"2023","unstructured":"Bakri SJ, Bektas M, Sharp D, Luo R, Sarda SP, Khan S. Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system. J Manag Care Spec Pharm. 2023;29:S2\u201311.","journal-title":"J Manag Care Spec Pharm"},{"key":"1397_CR3","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.ajo.2010.05.030","volume":"150","author":"AL Coleman","year":"2010","unstructured":"Coleman AL, Yu F, Ensrud KE, et al. Impact of age-related macular degeneration on vision-specific quality of life: follow-up from the 10-year and 15-year visits of the Study of Osteoporotic Fractures. Am J Ophthalmol. 2010;150:683\u201391.","journal-title":"Am J Ophthalmol"},{"key":"1397_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41433-021-01765-x","volume":"36","author":"D Desai","year":"2022","unstructured":"Desai D, Dugel PU. Complement cascade inhibition in geographic atrophy: a review. Eye. 2022;36:294\u2013302.","journal-title":"Eye"},{"key":"1397_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s40123-024-00899-x","volume":"13","author":"G Querques","year":"2024","unstructured":"Querques G, Amblard JC, Andrao A, et al. Expert consensus on geographic atrophy in the EU: a call for urgent policy action. Ophthalmol Ther. 2024;13:867\u201381.","journal-title":"Ophthalmol Ther"},{"key":"1397_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjophth-2024-001854","volume":"9","author":"E Lai","year":"2024","unstructured":"Lai E, Lee T, Lee C, Schechet SA. New horizons in geographic atrophy treatment: enthusiasm and caution surrounding complement inhibitors. BMJ Open Ophthalmol. 2024;9:e001854.","journal-title":"BMJ Open Ophthalmol"},{"key":"1397_CR7","doi-asserted-by":"publisher","first-page":"6628","DOI":"10.1167\/iovs.12-9587","volume":"53","author":"KM Loyet","year":"2012","unstructured":"Loyet KM, Deforge LE, Katschke KJ Jr., et al. Activation of the alternative complement pathway in vitreous is controlled by genetics in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2012;53:6628\u201337.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1397_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s00281-017-0655-8","volume":"40","author":"CL Harris","year":"2018","unstructured":"Harris CL. Expanding horizons in complement drug discovery: challenges and emerging strategies. Semin Immunopathol. 2018;40:125\u201340.","journal-title":"Semin Immunopathol"},{"key":"1397_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00431-y","volume":"8","author":"T Yednock","year":"2022","unstructured":"Yednock T, Fong DS, Lad EM. C1q and the classical complement cascade in geographic atrophy secondary to age-related macular degeneration. Int J Retina Vitreous. 2022;8:79.","journal-title":"Int J Retina Vitreous"},{"key":"1397_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-25557-8","volume":"8","author":"KJ Katschke Jr.","year":"2018","unstructured":"Katschke KJ Jr., Xi H, Cox C, et al. Classical and alternative complement activation on photoreceptor outer segments drives monocyte-dependent retinal atrophy. Sci Rep. 2018;8:7348.","journal-title":"Sci Rep"},{"key":"1397_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/978-3-319-75402-4_4","volume":"1074","author":"R Fernandez-Godino","year":"2018","unstructured":"Fernandez-Godino R. Alterations in extracellular matrix\/Bruch\u2019s membrane can cause the activation of the alternative complement pathway via tick-over. Adv Exp Med Biol. 2018;1074:29\u201335.","journal-title":"Adv Exp Med Biol"},{"key":"1397_CR12","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.61.8.15","volume":"61","author":"VL Bonilha","year":"2020","unstructured":"Bonilha VL, Bell BA, Hu J, et al. Geographic atrophy: confocal scanning laser ophthalmoscopy, histology, and inflammation in the region of expanding lesions. Invest Ophthalmol Vis Sci. 2020;61:15.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1397_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ajo.2024.02.021","volume":"263","author":"KG Csaky","year":"2024","unstructured":"Csaky KG, Miller JML, Martin DF, Johnson MW. Drug approval for the treatment of geographic atrophy: how we got here and where we need to go. Am J Ophthalmol. 2024;263:231\u20139.","journal-title":"Am J Ophthalmol"},{"key":"1397_CR14","unstructured":"Apellis Pharmaceuticals Inc. Apellis receives approval of SYFOVRE\u00ae (pegcetacoplan) in Australia for geographic atrophy (GA). 2025. Accessed 20 May 2025, https:\/\/investors.apellis.com\/news-releases\/news-release-details\/apellis-receives-approval-syfovrer-pegcetacoplan-australia"},{"key":"1397_CR15","unstructured":"Astellas Pharma US Inc. IZERVAY\u2122 (avacincaptad pegol intravitreal solution) showed increased benefit in reducing geographic atrophy progression over time and consistent long-term safety. 2025. Accessed 19 November 2025, https:\/\/newsroom.astellas.com\/2025-10-19-IZERVAY-TM-avacincaptad-pegol-intravitreal-solution-Showed-Increased-Benefit-in-Reducing-Geographic-Atrophy-Progression-Over-Time-and-Consistent-Long-Term-Safety"},{"key":"1397_CR16","unstructured":"Astellas Pharma US Inc. Astellas receives conditional approval for IZERVAY, making it the first and only approved treatment for the suppression of geographic atrophy growth in Japan. 2025. Accessed 18 November 2025, https:\/\/newsroom.astellas.com\/2025-09-19-Astellas-Receives-Conditional-Approval-for-IZERVAY,-making-it-the-first-and-only-approved-treatment-for-the-Suppression-of-Geographic-Atrophy-Growth-in-Japan"},{"key":"1397_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12082870","volume":"12","author":"S Hammadi","year":"2023","unstructured":"Hammadi S, Tzoumas N, Ferrara M, et al. Bruch\u2019s membrane: a key consideration with complement-based therapies for age-related macular degeneration. J Clin Med. 2023;12:2870.","journal-title":"J Clin Med"},{"key":"1397_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01778","volume":"8","author":"SJ Clark","year":"2017","unstructured":"Clark SJ, McHarg S, Tilakaratna V, Brace N, Bishop PN. Bruch\u2019s membrane compartmentalizes complement regulation in the eye with implications for therapeutic design in age-related macular degeneration. Front Immunol. 2017;8:1778.","journal-title":"Front Immunol"},{"key":"1397_CR19","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1016\/j.ajpath.2014.07.017","volume":"184","author":"RF Mullins","year":"2014","unstructured":"Mullins RF, Schoo DP, Sohn EH, et al. The membrane attack complex in aging human choriocapillaris: Relationship to macular degeneration and choroidal thinning. Am J Pathol. 2014;184:3142\u201353.","journal-title":"Am J Pathol"},{"key":"1397_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00281-017-0649-6","volume":"40","author":"SJ Clark","year":"2018","unstructured":"Clark SJ, Bishop PN. The eye as a complement dysregulation hotspot. Semin Immunopathol. 2018;40:65\u201374.","journal-title":"Semin Immunopathol"},{"key":"1397_CR21","unstructured":"Vega C. APL-2 and complement inhibition; a potential treatment of PNH and other complement-mediated diseases. Presented at: Boulder Peptide Symposium; 26\u201329 September 2016. Boulder, United States. Oral presentation. Accessed 19 November 2025, https:\/\/apellismedicalhub.com\/pnh-congress-presentations-paroxsymal-nocturnal-hemoglobinuria-pnh\/boulder-peptide-symposium-2016\/apl-2-and-complement-inhibition-a-potential-treatment-of-pnh-and-other-complement-mediated-diseases-bsp-2016\/"},{"key":"1397_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.tips.2022.01.004","volume":"43","author":"C Lamers","year":"2022","unstructured":"Lamers C, Mastellos DC, Ricklin D, Lambris JD. Compstatins: the dawn of clinical C3-targeted complement inhibition. Trends Pharmacol Sci. 2022;43:629\u201340.","journal-title":"Trends Pharmacol Sci"},{"key":"1397_CR23","first-page":"273","volume":"632","author":"D Ricklin","year":"2008","unstructured":"Ricklin D, Lambris JD. Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol. 2008;632:273\u201392.","journal-title":"Adv Exp Med Biol"},{"key":"1397_CR24","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-1-62703-724-2_6","volume":"1100","author":"MM Ruseva","year":"2014","unstructured":"Ruseva MM, Heurich M. Purification and characterization of human and mouse complement C3. Methods Mol Biol. 2014;1100:75\u201391.","journal-title":"Methods Mol Biol"},{"key":"1397_CR25","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/B978-0-12-803620-4.00029-3","volume-title":"A comprehensive guide to toxicology in nonclinical drug development","author":"M Ferrell Ramos","year":"2017","unstructured":"Ferrell Ramos M, Attar M, Stern ME, et al. Safety evaluation of ocular drugs. In: Faqi AS, editor., et al., A comprehensive guide to toxicology in nonclinical drug development. Second edn. Boston: Academic Press; 2017. p. 757\u2013811.","edition":"Second edn"},{"key":"1397_CR26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, et al. Fiji: An open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"1397_CR27","doi-asserted-by":"publisher","first-page":"4616","DOI":"10.1021\/jm0603419","volume":"49","author":"M Katragadda","year":"2006","unstructured":"Katragadda M, Magotti P, Sfyroera G, Lambris JD. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem. 2006;49:4616\u201322.","journal-title":"J Med Chem"},{"key":"1397_CR28","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1007\/s11095-012-0763-z","volume":"29","author":"Y Singh","year":"2012","unstructured":"Singh Y, Gao D, Gu Z, et al. Influence of molecular size on the retention of polymeric nanocarrier diagnostic agents in breast ducts. Pharm Res. 2012;29:2377\u201388.","journal-title":"Pharm Res"},{"key":"1397_CR29","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00417-015-3041-z","volume":"253","author":"C Brockmann","year":"2015","unstructured":"Brockmann C, Brockmann T, Dege S, et al. Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice. Graefes Arch Clin Exp Ophthalmol. 2015;253:1695\u2013704.","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01397-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01397-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01397-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:03:07Z","timestamp":1785477787000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01397-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1397"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01397-y","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephanie Jungmichel reports a relationship with CDR-Life AG, Horgen, Switzerland, that includes: employment. Fabian Scheifele reports a relationship with CDR-Life AG, Horgen, Switzerland, that includes: employment and equity or stocks. Anna Sobieraj reports a relationship with CDR-Life AG, Horgen, Switzerland, that includes: employment. Philipp Richle reports a relationship with CDR-Life AG, Horgen, Switzerland, that includes: employment and equity or stocks. Daniel Lenherr-Frey reports a relationship with CDR-Life AG, Horgen, Switzerland, that includes: employment. Leonardo Borras reports a relationship with CDR-Life AG, Horgen, Switzerland, that includes: board membership, employment, and equity or stocks. Pankaj Gupta reports a relationship with Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, that includes: employment. Stefan Kreidewei\u00df reports a relationship with Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, that includes: employment. Remko A. Bakker reports a relationship with C. H. Boehringer Sohn AG & Co. KG, Biberach an der Riss, Germany, that includes: employment. Leonardo Borras has patent pending to CDR Life AG, Boehringer Ingelheim International GmbH. Pankaj Gupta has patent pending to CDR Life AG, Boehringer Ingelheim International GmbH. Stephanie Jungmichel has patent pending to CDR Life AG, Boehringer Ingelheim International GmbH. Philipp Richle has patent pending to CDR Life AG, Boehringer Ingelheim International GmbH. Fabian Scheifele has patent pending to CDR Life AG, Boehringer Ingelheim International GmbH. Anna Sobieraj has patent pending to CDR Life AG, Boehringer Ingelheim International GmbH. Stefan Kreidewei\u00df, Daniel Lenherr-Frey, and Remko Bakker have no patent and intellectual property disclosures to declare.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval was required for this study as it did not involve human participants or live animals.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}